Physiomics Plc (PYC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Physiomics Plc (PYC) has a cash flow conversion efficiency ratio of -0.514x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-202.00K ≈ $-24.58 USD) by net assets (GBX393.00K ≈ $47.82 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Physiomics Plc's balance sheet to measure how much of total assets are equity-financed.
Physiomics Plc - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Physiomics Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Physiomics Plc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Physiomics Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Physiomics Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Catenai PLC
LSE:CTAI
|
-0.188x |
|
Gaming Technologies Inc. Common Stock
NASDAQ:GMGT
|
0.110x |
|
Mobile Max-M
TA:MBMX
|
-3.104x |
|
Alina Holdings PLC
LSE:ALNA
|
-0.041x |
|
Hsin Yung Chien Co Ltd
TW:2114
|
0.010x |
|
Botswana Diamonds plc
LSE:BOD
|
-0.001x |
|
AMUR MINERALS (A7L.SG)
STU:A7L
|
N/A |
|
IQ-AI Ltd
LSE:IQAI
|
-0.220x |
Annual Cash Flow Conversion Efficiency for Physiomics Plc (2001–2025)
The table below shows the annual cash flow conversion efficiency of Physiomics Plc from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see PYC stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX692.17K ≈ $84.22 |
GBX-546.14K ≈ $-66.45 |
-0.789x | +59.33% |
| 2024-06-30 | GBX282.53K ≈ $34.38 |
GBX-548.13K ≈ $-66.69 |
-1.940x | -289.48% |
| 2023-06-30 | GBX531.72K ≈ $64.69 |
GBX-264.86K ≈ $-32.23 |
-0.498x | -39.03% |
| 2022-06-30 | GBX974.81K ≈ $118.61 |
GBX-349.25K ≈ $-42.49 |
-0.358x | -1185.23% |
| 2021-06-30 | GBX1.17 Million ≈ $141.83 |
GBX-32.50K ≈ $-3.95 |
-0.028x | +68.31% |
| 2020-06-30 | GBX1.31 Million ≈ $160.00 |
GBX-115.69K ≈ $-14.08 |
-0.088x | +62.80% |
| 2019-06-30 | GBX607.91K ≈ $73.97 |
GBX-143.77K ≈ $-17.49 |
-0.237x | +3.89% |
| 2018-06-30 | GBX690.03K ≈ $83.96 |
GBX-169.80K ≈ $-20.66 |
-0.246x | +81.53% |
| 2017-06-30 | GBX328.25K ≈ $39.94 |
GBX-437.27K ≈ $-53.20 |
-1.332x | +21.60% |
| 2016-06-30 | GBX204.15K ≈ $24.84 |
GBX-346.87K ≈ $-42.20 |
-1.699x | -40.90% |
| 2015-06-30 | GBX325.62K ≈ $39.62 |
GBX-392.65K ≈ $-47.77 |
-1.206x | +53.18% |
| 2014-06-30 | GBX136.49K ≈ $16.61 |
GBX-351.51K ≈ $-42.77 |
-2.575x | -25.62% |
| 2013-06-30 | GBX255.82K ≈ $31.13 |
GBX-524.49K ≈ $-63.81 |
-2.050x | -172.94% |
| 2012-06-30 | GBX734.57K ≈ $89.38 |
GBX-551.77K ≈ $-67.13 |
-0.751x | +11.68% |
| 2011-06-30 | GBX756.00K ≈ $91.98 |
GBX-643.00K ≈ $-78.23 |
-0.851x | -54.23% |
| 2010-06-30 | GBX787.00K ≈ $95.76 |
GBX-434.00K ≈ $-52.81 |
-0.551x | -80.29% |
| 2009-06-30 | GBX-85.00K ≈ $-10.34 |
GBX26.00K ≈ $3.16 |
-0.306x | -188.03% |
| 2008-06-30 | GBX-354.00K ≈ $-43.07 |
GBX-123.00K ≈ $-14.97 |
0.347x | +108.89% |
| 2007-06-30 | GBX99.00K ≈ $12.05 |
GBX-387.00K ≈ $-47.09 |
-3.909x | -194.51% |
| 2006-06-30 | GBX-66.00K ≈ $-8.03 |
GBX-273.00K ≈ $-33.22 |
4.136x | +499.14% |
| 2005-06-30 | GBX413.00K ≈ $50.25 |
GBX-428.00K ≈ $-52.08 |
-1.036x | -268.28% |
| 2004-06-30 | GBX-354.00K ≈ $-43.07 |
GBX-218.00K ≈ $-26.52 |
0.616x | -60.87% |
| 2003-06-30 | GBX-129.00K ≈ $-15.70 |
GBX-203.00K ≈ $-24.70 |
1.574x | +233.71% |
| 2001-06-30 | GBX130.00K ≈ $15.82 |
GBX-153.00K ≈ $-18.62 |
-1.177x | -- |
About Physiomics Plc
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour pred… Read more